Compared with single PD-L1 or PD-1 inhibition, dual immune checkpoint blockade with CTLA-4 and PD-L1 or PD-1 inhibitors was associated with improved overall survival in patients with advanced NSCLC and PD-L1 TPS less than 1% and in those with STK11 mutations, but not in the overall population. Prospective validation of these results in clinical trials is warranted.
[Articles] Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
The Lancet Oncology | | Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, Andrea De Giglio, Francesca Lo Bianco, Federica Pecci, Joao V Alessi, Xinan Wang, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Ferdinandos Skoulidis, Marina C Garassino, Solange Peters, Mark M Awad, Andrea Ardizzoni, Biagio Ricciuti
Topics: lung-cancer, blood-cancer, immunotherapy, targeted-therapy, clinical-trials, research